IL143516A0 - COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B - Google Patents

COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B

Info

Publication number
IL143516A0
IL143516A0 IL14351699A IL14351699A IL143516A0 IL 143516 A0 IL143516 A0 IL 143516A0 IL 14351699 A IL14351699 A IL 14351699A IL 14351699 A IL14351699 A IL 14351699A IL 143516 A0 IL143516 A0 IL 143516A0
Authority
IL
Israel
Prior art keywords
methods
activation
compounds
modulating
compositions
Prior art date
Application number
IL14351699A
Other languages
English (en)
Original Assignee
Signal Pharm Inc
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Inc, Yissum Res Dev Co filed Critical Signal Pharm Inc
Publication of IL143516A0 publication Critical patent/IL143516A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Transmitters (AREA)
IL14351699A 1998-12-10 1999-12-10 COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B IL143516A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21006098A 1998-12-10 1998-12-10
PCT/US1999/029371 WO2000034447A2 (en) 1998-12-10 1999-12-09 Human ubiquitin ligase e3 for the modulation of nf-kappa b

Publications (1)

Publication Number Publication Date
IL143516A0 true IL143516A0 (en) 2002-04-21

Family

ID=22781444

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14351699A IL143516A0 (en) 1998-12-10 1999-12-10 COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
IL143516A IL143516A (en) 1998-12-10 2001-05-31 E3 ubiquitin ligase polypeptide, polynucleotide encoding the same and uses thereof
IL187254A IL187254A (en) 1998-12-10 2007-11-08 ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL143516A IL143516A (en) 1998-12-10 2001-05-31 E3 ubiquitin ligase polypeptide, polynucleotide encoding the same and uses thereof
IL187254A IL187254A (en) 1998-12-10 2007-11-08 ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB

Country Status (12)

Country Link
US (4) US6656713B2 (xx)
EP (1) EP1135504B1 (xx)
JP (1) JP4633259B2 (xx)
KR (2) KR20070050995A (xx)
CN (2) CN102816743A (xx)
AT (1) ATE499445T1 (xx)
AU (2) AU779893B2 (xx)
CA (1) CA2354153C (xx)
DE (1) DE69943222D1 (xx)
ES (1) ES2361660T3 (xx)
IL (3) IL143516A0 (xx)
WO (1) WO2000034447A2 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008955A1 (en) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
EP1135504B1 (en) * 1998-12-10 2011-02-23 Signal Pharmaceuticals LLC Human ubiquitin ligase e3 for the modulation of nf-kappa b
AU2001281052A1 (en) * 2000-08-07 2002-02-18 Deltagen, Inc. Transgenic mice containing ubiquitin protein ligase e3 gene disruptions
EP1182251A1 (en) 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
AU2002240889A1 (en) * 2000-12-18 2002-07-01 Hybrigenics Proteins that interact with betatrcp
US7037936B2 (en) 2002-06-17 2006-05-02 Signal Pharmaceuticals, Llc. Compounds useful for the treatment of cancer, compositions thereof and methods therewith
US20060256599A1 (en) * 2005-03-22 2006-11-16 Malin Patricia J Database of electronically profiled cells and methods for generating and using same
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
EP1866329B1 (en) 2005-12-16 2010-05-26 National Cancer Center Peptides for inhibiting transglutaminase
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
US20130210875A1 (en) * 2012-02-10 2013-08-15 Macau University Of Science And Technology Novel binding site of IKK-beta
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US5597898A (en) 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
US5972674A (en) 1996-08-26 1999-10-26 Signal Pharmaceuticals, Inc. Stimulus-inducible protein kinase complex and methods of use therefor
WO1998008955A1 (en) 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US5851812A (en) 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235512B1 (en) 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6242253B1 (en) 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
FR2774378A1 (fr) * 1998-01-30 1999-07-30 Inst Nat Sante Rech Med PROTEINE HUMAINE BETA-TrCP DE CIBLAGE DES PROTEINES VERS LES VOIES DE DEGRADATION PAR LE PROTEASOME
EP1135504B1 (en) 1998-12-10 2011-02-23 Signal Pharmaceuticals LLC Human ubiquitin ligase e3 for the modulation of nf-kappa b
US6280623B1 (en) * 1999-03-23 2001-08-28 Hsien-Chih Ma Differential and continuous separation apparatus with controlled parameters for solids and liquids
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors

Also Published As

Publication number Publication date
CN102816743A (zh) 2012-12-12
ES2361660T3 (es) 2011-06-21
ATE499445T1 (de) 2011-03-15
US20040203098A1 (en) 2004-10-14
US20030166587A1 (en) 2003-09-04
EP1135504B1 (en) 2011-02-23
CN1346406A (zh) 2002-04-24
WO2000034447A3 (en) 2000-11-09
KR20020007284A (ko) 2002-01-26
US8263326B2 (en) 2012-09-11
KR20070050995A (ko) 2007-05-16
IL187254A (en) 2010-12-30
WO2000034447A2 (en) 2000-06-15
JP2002539766A (ja) 2002-11-26
AU779893B2 (en) 2005-02-17
US20090233855A1 (en) 2009-09-17
AU2004240212B2 (en) 2007-12-06
AU2004240212A8 (en) 2005-02-10
IL143516A (en) 2010-11-30
US20070208167A1 (en) 2007-09-06
DE69943222D1 (de) 2011-04-07
US7186503B2 (en) 2007-03-06
US6656713B2 (en) 2003-12-02
WO2000034447A8 (en) 2001-07-12
EP1135504A2 (en) 2001-09-26
CA2354153A1 (en) 2000-06-15
AU2174000A (en) 2000-06-26
CA2354153C (en) 2011-04-12
AU2004240212A1 (en) 2005-02-10
US7414120B2 (en) 2008-08-19
KR100756689B1 (ko) 2007-09-07
WO2000034447A9 (en) 2002-08-29
JP4633259B2 (ja) 2011-02-16

Similar Documents

Publication Publication Date Title
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
PL328858A1 (en) Immunogenous peptides
AU2212299A (en) Compositions and methods for the treatment of tumor
BG104780A (en) Inhibitors of phospholipase enzymes
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69939864D1 (de) Ppar-gamma modulatoren
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
BG104392A (en) Methods for the modulation of serin/treonin protein kinase function with compounds based on 5-azaquinoxaline
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
AU6659198A (en) Compositions and methods for modulating cellular nf-$g(k)b activation
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
PL346246A1 (en) Modulating multiple lineage kinase proteins
AU2821295A (en) Compositions and methods for the treatment of tumors
GB9907571D0 (en) Compounds
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
AU7986098A (en) 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
DE69408394T2 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
IL139303A0 (en) Treatment of arthritis and other similar conditions
GB9814269D0 (en) 9a-Aza-3-ketolides, compositions containing such compounds and methods of treatment